Project Grant R01AR084536
Award Date
6/3/25
Completion Date
4/30/30
Dollars Obligated
$460K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $378,250 to The Children's Hospital of Philadelphia Research Institute to conduct research on regulating skeletal growth and regeneration. The project aims to assess growth plate dysfunction, delineate the underlying cellular mechanisms, and test the effectiveness and safety of...
This $662,241 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to address the gap in validated outcome measures and natural history for mitochondrial myopathy (MM). The primary objectives are to: 1) obtain longitudinal data on the MM Composite Assessment Tool (MM-COAST) and MM Function Scale to define their minimum...
This federal Project Grant award, totaling $1,938,605, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The objective of the award is to determine the mechanisms by which the X-linked chromatin modifying enzyme KDM5C regulates female bone mass. The research aims to investigate how loss of KDM5C affects osteoclast function, communication between osteoclasts and...
This Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research into the metabolic regulation of osteoclast differentiation and bone resorption. The $588,302 award, effective from February 1, 2025 to January 31, 2030, aims to: 1) establish the necessity and sufficiency of glutaminase (GLS)-dependent glutamine metabolism in regulating...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $221,484 to The Children's Hospital of Philadelphia Research Institute to conduct research on the roles of the RUNX2 and RUNX3 transcription factors in regulating skeletal growth plate development and patterning. The 3-year project aims to comprehensively define the skeletal...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is for a study titled "Targeting Mitochondrial Permeability Transition to Attenuate Adverse Muscle Impact in Sepsis". The $193,188 award, effective from Sep 1, 2024 to Aug 31, 2026, will investigate the role of mitochondrial permeability transition (MPT) in skeletal muscle dysfunction...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $624,004.07 to Thomas Jefferson University (doing business as Sidney Kimmel Medical College) to conduct research on the role of HIF-1 in intervertebral disc function. The key objectives are to delineate the mechanisms by which HIF-1 regulates glucose availability and...
This Project Grant award for $144,362 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the critical factors regulating the fate determination of chondrocyte progenitor cells during synovial joint and bone development. The objectives of the study are to determine: 1) the extent to which candidate transcription factors like PITX1 and ATF4...
This federal Project Grant award of $219,605.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify the role of the mechanosensitive ion channel PIEZO1 in driving synovial fibrosis and inflammation in post-traumatic osteoarthritis (PTOA). The research will characterize the bi-directional regulation between PIEZO1 mechanotransduction and...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $206,023 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Cornell University to investigate mechanotransduction pathways in injured cartilage. The project aims to determine how local peak strain magnitude and manipulation of calcium-dependent signaling or mitochondrial bioenergetics affect the distribution of chondrocyte phenotypes after impact injury, using a novel...